TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from HCW Biologics ( (HCWB) ) is now available.
On November 17, 2025, HCW Biologics Inc. and Beijing Trimmune Biotech Co., Ltd. entered into an Amended and Restated License, Research and Co-Development Agreement. This agreement involves restructuring the original license to include rights assignment to Trimmune, a $3.5M cash payment, and an equity transfer. HCW retains an option to recapture rights in the Americas post-Phase 1 trials, while Trimmune handles all development costs in its territory. If the deal doesn’t close by January 16, 2026, rights revert to HCW.
The most recent analyst rating on (HCWB) stock is a Sell with a $3.00 price target. To see the full list of analyst forecasts on HCW Biologics stock, see the HCWB Stock Forecast page.
Spark’s Take on HCWB Stock
According to Spark, TipRanks’ AI Analyst, HCWB is a Underperform.
HCW Biologics is facing significant financial and operational challenges, with declining revenues and high leverage. Technical indicators suggest bearish momentum, and valuation metrics highlight ongoing losses. These factors contribute to a low overall stock score, indicating a high-risk investment with substantial hurdles to overcome.
To see Spark’s full report on HCWB stock, click here.
More about HCW Biologics
HCW Biologics Inc. operates in the biotechnology industry, focusing on the development and commercialization of innovative biologic therapies.
Average Trading Volume: 1,889,866
Technical Sentiment Signal: Sell
Current Market Cap: $8.27M
For detailed information about HCWB stock, go to TipRanks’ Stock Analysis page.